Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program

Area of Science:

• Immunology
• Health Economics
• Pharmacoeconomics

Background:

• Subcutaneous immunoglobulin (SCIG) therapy is crucial for managing various immune deficiencies.
• Clinical management programs aim to optimize patient care and resource utilization for SCIG therapy.
• Evaluating the comparative effectiveness and cost-efficiency of these programs is essential for healthcare providers and payers.

Purpose of the Study:

• To compare clinical and cost outcomes of SCIG therapy patients managed within a clinical program versus matched controls.
• To assess the impact of a high-touch SCIG management program on adverse events and healthcare expenditures.
• To provide evidence for the value proposition of SCIG management programs in the US healthcare landscape.

Main Methods:

• Retrospective cohort study utilizing administrative claims data from the PharMetrics Plus™ (PMTX+) database.
• Propensity score matching (1:4 ratio, without replacement) was employed to create comparable intervention and control groups.
• Generalized estimating equation models were used to compare clinical (infection- and infusion-related adverse events) and cost outcomes over a 1-year follow-up period.

Main Results:

• No significant differences were observed in most infection- and infusion-related adverse events between the SCIG management program group and controls (P > 0.05).
• A higher proportion of mild, less common adverse events was noted in the intervention group (4.4% vs. 0.0%; P = 0.04), potentially due to increased reporting.
• The SCIG management program was associated with significantly lower annual adjusted mean total healthcare costs ($66,450 vs. $87,318; P = 0.009), a reduction of 24% or $20,868 per patient.

Conclusions:

• Clinical management programs for SCIG therapy may be linked to reduced healthcare costs.
• These programs appear to offer comparable rates of infection and severe adverse events compared to standard care.
• Limitations include a small sample size and reliance on administrative claims data, warranting further investigation.